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Introduction {#sec1}
============

Resident neural stem cells (NSCs) in the adult brain produce new neurons and glia and display two fundamental features: multipotency and long-term self-renewal capacity. Characterization of the adult neurogenesis process has shed light on the importance of accurate NSCs control in brain homeostasis, behavior, and brain repair/regeneration ([@bib34], [@bib41]). In the adult mouse brain, NSCs are found primarily in two microenvironmental niches located in the telencephalon: the subependymal zone (SEZ) of the lateral ventricle and the subgranular zone (SGZ) of the dentate gyrus of the hippocampus ([@bib34]). By contrast, in the zebrafish, which is emerging as an attractive comparative model, widespread neurogenesis is maintained at adult stages in several brain regions ([@bib1], [@bib26]), including the dorsal telencephalon (or pallium), which encompasses areas homologous to the rodent SEZ and SGZ ([@bib19]). In this region, radial glia cells (RG), constituting a large population that lines the surface of the brain ventricle, have been identified as NSCs ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). These cells share features with NSCs found in the mammalian brain including their radial morphology, the expression of astroglial markers (GFAP, GS, BLBP), and neurogenic stem cell markers (Sox2, Nestin, Msi1, and the zebrafish *Hes5* ortholog, *her4*) ([@bib11], [@bib24], [@bib38], [@bib2], [@bib19], [@bib60]). Lineage tracing and clonal analyses have revealed that these NSCs contribute to constitutive adult neurogenesis and are able to self-renew and give rise to functional neurons at the single cell level, both qualifying them as genuine stem cells and demonstrating their robust neurogenic activity ([@bib31], [@bib51]).

A distinguishing feature of adult NSCs when compared with embryonic neural progenitor cells (NPCs), both in zebrafish and mammals, is their relative quiescence. Quiescence is a reversible state of cell-cycle arrest, which is actively maintained and involves profound alterations in cell physiology ([@bib12]). Disrupting the balance between quiescent and activated NSCs leads to a premature depletion or silencing of long-lasting NSCs ([@bib15], [@bib20], [@bib27]). Some key signaling or cell-cell interaction pathways, notably Notch and TGFβ/BMP ([@bib25]), have been identified in maintaining quiescence. In particular, in the zebrafish adult pallium, inhibiting Notch signaling leads the entire population of NSCs to enter the cell cycle ([@bib2]). Recent works further demonstrated that quiescent NSCs are heterogeneous in their activation potential, their reactivity to various stimuli and, once activated, their division rate and ability to re-enter into quiescence ([@bib27], [@bib36]). However, how quiescence cues are integrated to establish this cell state and the diversity within it have yet to be assessed.

MicroRNAs are small regulatory RNAs that are known to post-transcriptionally regulate gene expression via complementary base pairing with mRNA targets ([@bib4]). Canonical microRNA genes are transcribed into primary transcripts (pri-miRs) containing a hairpin structure, which is cleaved out by the nuclear microprocessor complex to give rise to a precursor microRNA (pre-miR). Exportin 5 transports the pre-miR to the cytoplasm where the RNase III enzyme Dicer processes it into a mature microRNA duplex. The duplex is subsequently unwound, and one strand is preferentially integrated into the RNA-induced silencing complex (RISC), which guides it to mRNA targets. The RISC is most notably composed of one Argonaute (Ago) effector protein, inside which the microRNA strand is loaded, and one GW182 protein (or TNRC6), which mediates downstream steps in the cascade of microRNA-mediated gene regulation ([@bib40]). Because microRNAs can potentially regulate hundreds of mRNA targets, they are generally thought of as fine-tuners of gene expression, buffering or reinforcing developmental and transitional states. Additionally, microRNA levels and functions are influenced by both cell extrinsic and intrinsic signals ([@bib44], [@bib50]). As such, microRNAs are attractive candidates for integrating environmental and internal cues in the regulation of NSCs quiescence/activation balance.

MicroRNA-9 (miR-9) is a highly conserved neural microRNA, shown to be a determinant regulator of NPCs during vertebrate embryonic development ([@bib17]). Expression of miR-9-5p (the preferred mature strand in vertebrate embryos, henceforth referred to simply as miR-9) is enriched to NPCs and committed neuronal precursors in the proliferative ventricular zone (VZ); it promotes the transition of NPCs from a proliferative to a neurogenic mode and is crucial in the timing of their cell-cycle exit ([@bib33], [@bib7], [@bib56], [@bib16]). Studies performed on mouse NSCs proliferating in vitro also suggested that it could play a similar role in adult NSCs dynamics ([@bib64]). To challenge this hypothesis in a physiological context in which adult NSCs are mostly quiescent, we assessed here the role of miR-9 in adult zebrafish NSCs in vivo. We show that miR-9 expression highlights a sub-state within the quiescence phase of adult NSCs, and we demonstrate that it maintains quiescence through potentiating Notch signaling activity. Remarkably, we also find that miR-9 controls this key stem cell property via a non-canonical nuclear mechanism.

Results {#sec2}
=======

miR-9 Is Expressed Exclusively in Quiescent Neural Stem Cells in the Adult Telencephalon {#sec2.1}
----------------------------------------------------------------------------------------

To determine whether miR-9 could also control transitional states in neural progenitors at late stages, we first assessed the expression of the seven primary transcripts encoding miR-9 (pri-miR-9) in embryonic, juvenile, and adult zebrafish brains using qRT-PCR. We could detect the seven pri-miR-9 transcripts at all stages. However, there was a progressive change in the respective contribution of the different transcripts to the total pri-miR-9 pool ([Figure 1](#fig1){ref-type="fig"}A). We found that pri-miR-9-6 is the most predominantly expressed miR-9 transcript in the adult brain, in contrast to the situation in the embryo, where pri-miR-9-2 is the most highly expressed. In situ hybridization (ISH) experiments confirmed that pri-miR-9-6 is highly expressed in the adult telencephalon whereas pri-miR-9-2 is not detectable ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}C). Notably, pri-miR-9-6 expression appeared restricted to the first cellular row lining the brain ventricle, composed of the radial glia (RG) that constitute the population of NSCs in this region of the brain ([Figure 1](#fig1){ref-type="fig"}B).

To define the expression of miR-9 at a cellular resolution, we performed fluorescent ISH experiments using an antisense LNA probe specific for the mature miR-9 form in combination with astroglial NSCs markers. In the zebrafish pallium, all RG NSCs can faithfully be labeled by immunohistochemistry against GFP in the *gfap:gfp* transgenic line or against glutamine synthase (GS) ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) ([@bib11], [@bib2]). In contrast to mammals, astrocytes and ependymal cells are absent from the zebrafish pallium, and the only cells that express these markers are RG NSCs ([@bib60]). In line with the expression of pri-miR-9-6, we could detect mature miR-9 exclusively in RG NSCs ([Figure 1](#fig1){ref-type="fig"}C). To confirm the specificity of the signal, we performed additional ISH using two control LNA probes (a scrambled control probe and a probe antisense to miR-9-3p) and two alternative LNA-modified 2′-O-Me RNA oligo probes ([@bib57]) (one control and one miR-9-specific probe). Altogether, these controls demonstrate both the specificity of our miR-9 probe and the stringency of our ISH protocol ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E) (LNA probes and their sequences are listed in [Table S2](#mmc1){ref-type="supplementary-material"}).

We next assessed the cycling status of miR-9-expressing NSCs using cycling cell markers such as MCM5, MCM2, or proliferating cell nuclear antigen (PCNA) that can be used interchangeably ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) ([@bib2], [@bib10], [@bib38]). Notably, miR-9-expressing NSCs are almost always quiescent NSCs (qNSCs) (95% ± 2%) ([Figure 1](#fig1){ref-type="fig"}C, red arrows), and we could validate a statistically significant association between miR-9 expression and the quiescent state (χ^2^ p value \< 0.01) ([Figures 1](#fig1){ref-type="fig"}C and 1D). In addition, and in contrast to all other NSC markers known to date, miR-9 was found to be expressed only in 47% ± 2% of the overall qNSCs, highlighting a striking heterogeneity in this quiescent population ([Figure 1](#fig1){ref-type="fig"}E).

miR-9 expression in a subpopulation of qNSCs could define a distinct NSC sub-lineage, or rather a sub-state in the quiescence cycle of all NSC. To investigate these hypotheses, we interrogated the dynamics of miR-9 expression in NSC in link with their activation history. We applied a short pulse (2 hr) of the thymidine analog bromodeoxyuridine (BrdU), which incorporates into the DNA of dividing cells during S-phase, followed by chase periods of increasing lengths from 1 to 30 days. We then analyzed the expression of miR-9 among BrdU^+^ NSCs ([Figures 1](#fig1){ref-type="fig"}F--1H). After 1 day of chase, no miR-9 was detected in the BrdU^+^ NSCs ([Figure 1](#fig1){ref-type="fig"}H), consistent with the very rare presence of miR-9 expression in dividing glia ([Figure 1](#fig1){ref-type="fig"}D). After longer chase periods, miR-9 and BrdU double positive NSCs start to be apparent ([Figure 1](#fig1){ref-type="fig"}G, yellow arrow, 1 hr), establishing that miR-9 can be expressed in cells that had previously been actively cycling. The percentage of BrdU^+^ NSCs expressing miR-9 gradually increased with chase time, suggesting an asynchronous but progressive induction of miR-9 expression among NSCs after cell division, to reach a plateau at ∼50% ([Figure 1](#fig1){ref-type="fig"}H), matching the overall proportion of qNSCs that express miR-9 ([Figure 1](#fig1){ref-type="fig"}E). Knowing that most pallial NSCs are capable of dividing ([@bib2]), these data together reveal that expression of miR-9 highlights a specific sub-state of quiescence in which qNSCs dynamically progress through.

miR-9 Maintains Quiescence {#sec2.2}
--------------------------

Does miR-9 actually play some role in controlling NSC quiescence? To address this issue, we performed loss-of-function experiments. Vivo morpholino oligonucleotides (vivoMO) are covalently linked to a delivery moiety conferring them the ability to enter into a cell without the need for transfection. Injection of a vivoMO into the brain ventricle enables the modulation of gene expression in the first ventricular cell rows, most notably in the RG NSC layer ([@bib28]). We used a miR-9 antisense vivoMO that binds to the mature miR-9 rendering it essentially inactive. The sequence of this vivoMO is identical to the MO previously validated to efficiently inhibit miR-9 in zebrafish embryos, without showing any evidence for off-targets effects ([@bib30], [@bib33]) ([Table S1](#mmc1){ref-type="supplementary-material"}). By performing an ISH with the mature miR-9 antisense probe, we verified that the miR-9 vivoMO also efficiently and specifically blocks miR-9 in the adult pallium, for up to 3 days post injection (dpi) ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). To determine the effect of miR-9 knockdown (kd) we analyzed the ratios of NSC activation status by quantifying GFAP^+^/MCM5^−^ (qNSC) and GFAP^+^/MCM5^+^ (aNSC) in control vivoMO- and miR-9 vivoMO-treated brains. In conditions of miR-9 kd, we observed, on average, a 3-fold increase in the proportion of aNSCs that was maintained for as long as the vivoMO was active ([Figures 2](#fig2){ref-type="fig"}B and 2C). After 3 days of miR-9 kd, this increase in aNSCs parallels the proportion of qNSCs that endogenously express miR-9 demonstrating that almost all of the miR-9 expressing NSCs enter into the cycle thus establishing miR-9 as a potent regulator of quiescence. To confirm the specificity of the miR-9 vivoMO effect, we used a combination of vivoMOs designed to target Drosha-processing sites on pre-miR-9 sequences (processing MO1, MO6), thereby blocking miR-9 production ([Figure S2](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}). Upon injection, these morpholinos efficiently reduce mature miR-9 levels, both in embryos and in the adult pallium ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Consequently, and consistent with the effect of the vivoMO targeted against mature miR-9, a significant increase in the proportion of aNSCs is observed, confirming the specific effect of miR-9 kd on NSCs activation ([Figure S2](#mmc1){ref-type="supplementary-material"}E). We also verified that injections of vivoMOs do not induce any apoptosis or inflammatory reaction, a process known to activate NSCs in the zebrafish pallium ([Figure S2](#mmc1){ref-type="supplementary-material"}F) ([@bib29], [@bib32]), nor any induction of *gata3* expression ([Figure S2](#mmc1){ref-type="supplementary-material"}F), previously shown to mediate NSCs activation upon inflammation or lesion ([@bib29], [@bib32]). The increase in aNSCs observed upon miR-9 kd is thus not related to a regenerative response but rather a consequence of an imbalance in constitutive neurogenesis regulation.

Interestingly, at 5 dpi, the vivoMO appears to be no longer active in blocking miR-9 ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A) and the proliferation rate of NSCs returns to basal levels ([Figure 2](#fig2){ref-type="fig"}B). Nevertheless, the NSCs activated upon miR-9 blockade proceed through mitosis, as demonstrated by an increase in the total number of RG NSCs lining the VZ at 5 dpi ([Figure 2](#fig2){ref-type="fig"}D), which is also in agreement with most NSC divisions being symmetric in the short term ([@bib51]). To better appreciate the long-term effect of miR-9 blockade on neurogenesis, we administered BrdU for 48 hr after vivoMO injections and analyzed the fate of dividing cells 30 days later by immunohistochemistry against NSC and neuronal markers (GS and Hu, respectively). The raw number of BrdU^+^ cells per section was doubled in the miR-9 vivoMO condition as compared to controls ([Figure 2](#fig2){ref-type="fig"}E), which is consistent with the transient increase in proliferation we observed in the short term. However, there was no significant difference in the relative proportions of the different cell types generated between the two conditions ([Figure 2](#fig2){ref-type="fig"}F). This shows that upon miR-9 blockade, NSCs only increase their propensity to enter the cell cycle, while their fate potential and clonal behavior appear unchanged. Overall, these data reveal that the primary role of miR-9 is maintaining quiescence of NSCs.

miR-9 Potentiates Notch Signaling to Promote Quiescence {#sec2.3}
-------------------------------------------------------

Zebrafish pallial NSC quiescence is maintained through active Notch signaling ([@bib11], [@bib2]). To investigate the relationship between miR-9 and Notch, we first analyzed the effect of Notch blockade on miR-9 expression: fish were treated for 48 hr with LY411575 (LY), a potent derivative of the γ-secretase inhibitor DAPT, which efficiently blocks Notch signaling and consequently pushes qNSCs into cell cycle re-entry ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B) ([@bib2]). qRT-PCR experiments revealed that the levels of the seven pri-miR-9 transcripts were not affected by Notch inhibition, in contrast to the direct Notch target gene *her4* ([Figure 3](#fig3){ref-type="fig"}A). Additionally, Notch inhibition had no effect on mature miR-9 levels ([Figure 3](#fig3){ref-type="fig"}B), establishing that miR-9 expression is not regulated by Notch in adult NSCs. These results were surprising as inhibiting Notch using LY leads to a significant increase in aNSCs and miR-9 is normally never endogenously expressed in these cells ([Figure 1](#fig1){ref-type="fig"}D). To investigate this discrepancy, we analyzed the expression of miR-9 in NSCs by ISH upon Notch blockade. In contrast to the control situation, we could observe miR-9 expression in PCNA^+^ cells that were activated upon Notch blockade ([Figure 3](#fig3){ref-type="fig"}C, yellow arrow). In fact, upon LY treatment, a similar proportion of activated cells is observed among miR-9^+^ or miR-9^−^ NSCs, and there is a loss of the preferential association of miR-9 with the quiescent state (DMSO: χ^2^ p value \< 0.05; LY: χ^2^ p value = 0.87) ([Figure 3](#fig3){ref-type="fig"}D). Downregulation of miR-9 is thus not an absolute requirement for cell-cycle entry, at least in this context. Moreover, these data demonstrate that when Notch signaling is impaired, miR-9 is no longer able to inhibit cell-cycle entry thus suggesting that miR-9 could act upstream of Notch in quiescence regulation. In line with this idea, we observed that the expression of the Notch effector *her4* is downregulated upon miR-9 kd ([Figure 3](#fig3){ref-type="fig"}E), as well as the expression of another known Notch target gene encoding the Notch-regulated ankyrin repeat protein (*nrarpa*) ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). By contrast, we do not observe a concomitant decrease in the expression of the *notch3* receptor gene, the main *notch* receptor gene expressed in qNSCs ([@bib2]) ([Figure S3](#mmc1){ref-type="supplementary-material"}C). To further challenge our hypothesis, we performed epistasis experiments in which we assessed the effect of miR-9 kd in NSCs with constitutively activate Notch signaling. Ventricular NSCs were electroporated with an expression construct encoding a Myc-tagged Notch intracellular domain (NICD) ([@bib59]), followed by injection of the miR-9 vivoMO. We observed that overexpression of NICD locks NSCs in a quiescent state, as expected, and also erases the activating effect of miR-9 depletion ([Figure 3](#fig3){ref-type="fig"}F). Altogether, our results suggest that miR-9 maintains NSC quiescence by potentiating Notch activation ([Figure S3](#mmc1){ref-type="supplementary-material"}F).

miR-9 Is Concentrated in the Nucleus of Mature RG NSCs and Is Strongly Associated with Nuclear Localization of Ago Proteins {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------

When analyzing the expression of miR-9 in the adult pallial NSCs, we made the surprising observation that mature miR-9 molecules were strongly concentrated in the nuclei of qNSCs ([Figure 4](#fig4){ref-type="fig"}A, yellow arrow) (as stated previously, miR-9 is not detectable in aNSCs) ([Figure 4](#fig4){ref-type="fig"}A, red arrow). This result was unexpected, as canonically, mature microRNAs influence gene expression via post-transcriptional regulation of mRNA in the cytoplasm ([@bib4]). Importantly, we observed no nuclear concentration of miR-9-3p in ventricular NSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}D) thus arguing against a nuclear trapping of unprocessed pri-miRs. In addition, we assessed the expression of another neurogenic microRNA, let-7b, whose expression pattern in the zebrafish embryo closely resembles that of miR-9 ([@bib63]). In the adult pallium, we found let-7b expression to be localized to the first ventricular rows, encompassing RG cells and differentiating neuronal precursors ([Figure S4](#mmc1){ref-type="supplementary-material"}A); however, in contrast to miR-9, let-7b localizes almost exclusively to the cytoplasm ([Figure S4](#mmc1){ref-type="supplementary-material"}A′). The localization of miR-9 in adult NSC nuclei is also in complete contrast to the exclusively cytoplasmic localization of miR-9 in embryonic or juvenile pallial neural progenitors (NPCs) ([Figure 4](#fig4){ref-type="fig"}B). The specific nuclear enrichment of mature miR-9 in adult NSCs compared to juvenile NSCs was also confirmed by qRT-PCR on cytoplasmic and nuclear fractions ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These data reveal a switch in the subcellular localization of miR-9, from the cytoplasm of NPCs to the nucleus of mature qNSCs, further reinforcing a link between miR-9 and a distinct quiescent state.

To assess the functional relevance of this observation, we reasoned that active miR-9 should be loaded into Argonaute proteins (Ago), the main effectors of the microRNA silencing pathway ([@bib40]), and therefore analyzed the subcellular localization of Ago proteins in the zebrafish pallium. We utilized two independent Ago antibodies that recognize highly conserved portions spanning the PIWI and most of the MID domains of human Ago2 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Both detect a band at the expected size in western blot (WB) from adult brain extracts, matching the size of overexpressed zebrafish Flag-Ago2 ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E, red arrows). Additionally, when performing immunohistochemistry on adult NSCs electroporated in vivo with a Flag-Ago2 expression construct, we observed overlapping signals for Flag and Ago ([Figure S4](#mmc1){ref-type="supplementary-material"}G). As the C-terminal portion is highly conserved among all vertebrate Agos, however ([Figure S4](#mmc1){ref-type="supplementary-material"}C), we cannot preclude that our antibodies label other Ago proteins than Ago2, and indeed, they have been shown previously to detect other Agos (1, 3, and 4) in human samples ([@bib22], [@bib45]); we thus refer to "Ago" staining below. Strikingly, we observed that Agos are highly expressed in the nuclei of a subset of NSCs ([Figure 4](#fig4){ref-type="fig"}D, yellow arrows) while in other NSCs the expression of Agos is either exclusively cytoplasmic ([Figure 4](#fig4){ref-type="fig"}D, white asterisk) or diffuse throughout the cell ([Figure 4](#fig4){ref-type="fig"}D, gray arrow). Importantly, the presence of Agos in cell nuclei was validated using both Ago antibodies ([Figure S4](#mmc1){ref-type="supplementary-material"}F) and confirmed by subcellular fractionation of proteins from telencephalic extracts ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We also observed a nuclear enrichment of Agos in neurons located in the deep brain parenchyma, strikingly associated with the nuclear localization of neuronal microRNAs such as miR-128 ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Notably, the presence of Agos in nuclei was restricted to adult stages, as Agos are exclusively located in the cytoplasm of juvenile NPCs and neurons ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

Focusing on NSCs, we could show that, like miR-9, nuclear Ago staining is significantly associated with quiescence and we rarely see Agos in the nucleus of aNSCs ([Figures S5](#mmc1){ref-type="supplementary-material"}E and S5F). Importantly, we also observed a strong association between the localization of Agos and miR-9 (χ^2^ p value \< 0.01) ([Figure 4](#fig4){ref-type="fig"}C): in miR-9-expressing qNSCs Agos are mostly found in the nucleus ([Figure 4](#fig4){ref-type="fig"}D, yellow arrows), while in miR-9-negative NSCs Agos are mostly cytoplasmic ([Figure 4](#fig4){ref-type="fig"}D, white asterisk and gray arrow). Lastly, and remarkably, when we knock down miR-9 we find a significant reduction in the proportion of NSCs displaying high levels of Agos in the nucleus (control MO = 29% ± 8%; miR-9 MO = 7% ± 4%) ([Figures 4](#fig4){ref-type="fig"}E and 4F). By contrast, we still observe a nuclear localization of Agos in neuronal cells of the parenchyma, demonstrating that this effect is specific to ventricular cells ([Figure 4](#fig4){ref-type="fig"}E, asterisks). This further strengthens the correlation between nuclear miR-9 and nuclear Agos; yet, based on these data, we cannot rule out the possibility that the change of Ago localization upon miR-9 kd is an indirect result of the increase in aNSCs number, which never have nuclear Agos.

Ago Proteins Actively Shuttle between the Cytoplasm and Nucleus that Impacts miR-9 Localization {#sec2.5}
-----------------------------------------------------------------------------------------------

To test the biological relevance of nuclear Agos in link with the control of NSC quiescence, we first examined whether active nuclear/cytoplasmic shuttling of Agos occurs in vivo in qNSCs. Recently, an essential protein component of the RISC, TNRC6A (GW182), was shown to shuttle Ago2 between the cytoplasm and the nucleus in human HeLa cells, while being re-cycled out of the nucleus in an Exportin 1-dependent manner ([@bib46]). We cloned a region spanning two of the GW regions of the zebrafish *tnrc6a* gene ([Figure 5](#fig5){ref-type="fig"}A) and fused it with a GFP tag. These two GW domains were previously demonstrated to mediate binding of TNRC6A to Ago proteins in mammals ([@bib21]). We confirmed by co-immunoprecipitation experiments in zebrafish embryos that the GFP-fused protein fragment binds both overexpressed FLAG-tagged Ago2 and endogenous zebrafish Ago proteins ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Moreover, overexpression of this construct in embryos dose-dependently interferes with miRNA silencing as shown in sensor assays ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Importantly, the TNRC6 fragment lacks a nuclear localization signal, hence is unable to enter into the nucleus thus acting as a dominant-negative TNRC6 (DN-TNRC6) cytoplasmic Ago-trap. To preferentially target qNSCs, we placed this construct under the promoter of the Notch-target gene *her4* (*her4:dn-tnrc6-gfp*) and electroporated it into the VZ of the adult pallium. In contrast to GFP, the DN-TNRC6-GFP fusion protein localizes mostly cytoplasmically ([Figure 5](#fig5){ref-type="fig"}B, white arrow). Strikingly, Agos were rarely nuclear in the NSCs that received *her4:dn-tnrc6-gfp* (12% ± 8%; [Figure 5](#fig5){ref-type="fig"}B, white arrow), as opposed to NSCs electroporated with the control *her4:gfp* (64% ± 5%; [Figure 5](#fig5){ref-type="fig"}B, yellow arrow) thus confirming cytoplasmic trapping of Agos ([Figures 5](#fig5){ref-type="fig"}B and 5C). Additionally, miR-9 expression is completely absent from the nuclei of the RG electroporated with *her4:dn-tnrc6-gfp* ([Figures 5](#fig5){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}C). Next, in a reciprocal experiment, we inhibited Exportin 1 by injecting Leptomycin B (LMB) into the brain ventricle. This treatment led to a significant increase in NSCs displaying a strong nuclear Ago signal ([Figure 5](#fig5){ref-type="fig"}E, yellow arrowheads; quantified in [Figure 5](#fig5){ref-type="fig"}F) thus establishing that Agos can be transported to and maintained in the nucleus. LMB administration concomitantly increased the number of cells displaying a strong nuclear signal for miR-9 ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). In sum, we were able to demonstrate that an active shuttling of Agos does indeed occur in vivo in NSCs, and specifically, their nuclear export is dependent on Exportin-1 and their nuclear import requires an interaction with TNRC6. Moreover, our data also indicate that the presence of miR-9 in the nucleus is reliant on nuclear Agos.

The Nuclear Localization of miR-9/Agos Is Necessary for NSC Quiescence {#sec2.6}
----------------------------------------------------------------------

Next, we wanted to evaluate whether manipulating the ratio of nuclear to cytoplasmic Agos in NSCs impacts cell state. To do this, we assessed the levels of NSC activation in the LMB-treated and *her4:dn-tnrc6-gfp*-electroporated brains. In the context of LMB-treated brains, the increased nuclear concentration of Agos and miR-9 was correlated with a significant increase in NSC quiescence ([Figures 5](#fig5){ref-type="fig"}E and 5G). In epistasis experiments, this increase in quiescence was rescued by injection of miR-9 vivoMO, thus establishing a causal link between maintaining miR-9/Agos complexes in the nucleus and the quiescent state ([Figure 5](#fig5){ref-type="fig"}H). By contrast, we found that NSCs overexpressing DN-TNRC6 were 2.5-fold more likely to enter into the cell cycle when compared with control NSCs expressing GFP ([Figures 5](#fig5){ref-type="fig"}B and 5I). Notably, the fold increase in NSC activation that was reached upon expressing DN-TNRC6 matches the one observed in conditions of miR-9 kd ([Figure 2](#fig2){ref-type="fig"}B). Moreover, knocking down miR-9 in conditions in which Ago/miR-9 complexes are excluded from the nucleus, via application of the miR-9 vivoMO after electroporation of DN-TNRC6, does not show an additive effect on proliferation ([Figure 5](#fig5){ref-type="fig"}J). This second epistasis experiment further indicates that nuclear miR-9 is indeed the active miR-9 pool in NSC quiescence control. Altogether, these data suggest that Agos and miR-9 require each other to be actively and concomitantly shuttled from the nucleus to the cytoplasm in a TNRC6-dependent manner, and their subcellular localization impacts cell state. In addition, their presence in the nucleus is coupled with increased levels of quiescence.

Nuclear miR-9 and Ago Localization Are Conserved in Quiescent NSCs of the Adult Mouse Brain {#sec2.7}
-------------------------------------------------------------------------------------------

Adult NSCs in the zebrafish and mammalian pallium share molecular and cellular similarities, including their dependence on Notch signaling for quiescence ([@bib60]), suggesting that the miR-9/Ago process discovered above may also be shared. To address this, we examined whether the nuclear localization of miR-9 and Agos is conserved and linked with quiescence control in adult mouse NSCs. At a global level, ISH experiments revealed the expression of miR-9 to be high in the SEZ and DG, the two known areas of constitutive neurogenesis in the adult mammalian brain ([Figure S7](#mmc1){ref-type="supplementary-material"}A). No signal was obtained using a control scrambled probe, demonstrating the specificity of our staining ([Figure S7](#mmc1){ref-type="supplementary-material"}B). We then analyzed the expression of miR-9 in conjunction with GFAP and Sox2, a SRY-related HMG box family member transcription factor demonstrated to be expressed in NSCs (quiescent and activated) of the DG and SEZ ([@bib27], [@bib58]). Strikingly, we observe miR-9 in the nucleus of a subset of NSCs in both regions ([Figures 6](#fig6){ref-type="fig"}A and 6B, yellow arrows). In contrast to what we observed in zebrafish, miR-9 appears to be additionally expressed in other cell types, although with a cytoplasmic localization. Very infrequently Sox2^+^ NSCs are found to be actively proliferating and express Ki67, however, like in zebrafish, we did not detect miR-9 in the nucleus of these aNSCs ([Figure S7](#mmc1){ref-type="supplementary-material"}C). We also compared the proportion of GFAP^+^ Sox2^+^ NSCs that express miR-9 in the nucleus between young (2-month-old) and older (10-month-old) mice in the DG. Interestingly, we observed a significant increase in miR-9 nuclear localization, suggesting a maturation-associated shift in the subcellular localization of miR-9 ([Figure 6](#fig6){ref-type="fig"}C). Overall, this in vivo data suggest that, like in zebrafish NSCs, nuclear miR-9 is associated with a mature quiescent NSC state in the mouse brain.

In the DG, BMP signaling maintains NSC quiescence and cultured NSCs from mice and rats have been shown to enter into a state of reversible cell-cycle arrest when treated with BMP ligands ([@bib42], [@bib37]). Transcriptomic analysis demonstrated that this cell-cycle arrest is equivalent to endogenous quiescence ([@bib37]) thus making these cells an ideal tool in which to probe the subcellular localization of Agos and miR-9 upon synchronous quiescence entry. For our analysis, we utilized in vitro NSCs isolated from the DG of adult mice (AH-NSCs). When cultured in the presence of the mitogen epidermal growth factor (EGF), these AH-NSCs are actively proliferating as demonstrated by the expression of the cell-cycle marker MCM2 ([Figure S7](#mmc1){ref-type="supplementary-material"}D). These cells, when cultured for 3 days without EGF and in the presence of BMP4, downregulate MCM2 and upregulate GFAP expression ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E). We could observe that proliferating NSCs tend to display low levels of Agos and miR-9 inside their nuclei, while quiescent AH-NSCs display a dramatic increase in the nuclear concentration of Ago2 and miR-9 ([Figure 6](#fig6){ref-type="fig"}D). Quantitative analysis shows that up to 60% of AH-NSCs harbor strong nuclear signals for Agos and miR-9 when they are induced to quiescence by BMP4 ([Figures 6](#fig6){ref-type="fig"}E and 6F). The increase in nuclear localization of these two factors was confirmed by automated quantification of relative signal intensities in cytoplasmic and nuclear compartments ([Figure 6](#fig6){ref-type="fig"}G). By contrast, we did not detect any significant change in total levels of Ago2 protein ([Figure S7](#mmc1){ref-type="supplementary-material"}F). Altogether, these in vivo and in vitro data point to a conserved association between nuclear Agos and miR-9 with quiescence in murine NSCs.

Discussion {#sec3}
==========

Our study identifies a microRNA, miR-9, as a critical player in the regulation of zebrafish pallial NSCs quiescence, a defining and protective feature of adult tissue stem cells ([@bib12]). Other microRNAs have been shown to be pivotal in regulating the proliferative behavior of adult tissue stem cells, such as in the muscle ([@bib13], [@bib18], [@bib52]) or skin ([@bib62]). Interestingly, in our case, we also observed that miR-9 is expressed in only half of the qNSCs. Further, BrdU pulse-chase experiments demonstrated that, after cell division, there is a short refractory period after which miR-9 expression is progressively induced in NSCs. The proportion of miR-9-expressing cells in the BrdU label-retaining NSCs never exceeds this of the overall NSCs population, indicating that miR-9 expression highlights a transitory phase qNSCs shuttle through. Our data thus highlight the importance of division history and temporal competence for the establishment of miR-9 expression in qNSCs and identify miR-9 as a molecular marker of a heterogeneity among qNSCs. Previous studies applying genetic labeling and lineage tracing have demonstrated that NSCs in the adult mouse DG are also heterogeneous in their activation potential and contribution to long-term neurogenesis ([@bib25], [@bib36]). Unveiling the precise properties linked with miR-9 expression, in terms of differential molecular control of activation and fate potential upon division will ultimately help understanding the establishment of heterogeneity within qNSCs and its functional significance for NSCs population dynamics.

Many similarities and differences between the nature and regulation of embryonic NPCs and adult NSCs have been identified ([@bib61]), however, the modifications in stem cell properties and molecular control between juvenile and adult stages are still rather understudied. Interestingly, a recent study revealed a progressive change in the expression of cell-cycle regulators in BLBP-positive RG during post-natal stages in mice, directly influencing the competence of these cells to be transformed by oncogenes ([@bib43]). Moreover, a change in microRNAs signature occurs in muscle satellite stem cells between juvenile and adult stages and correlates with a modification of cell-cycle dynamics ([@bib52]). Our data provide important molecular insights on this transition. First, we show that the relative expression of the miR-9 primary transcripts changes progressively from the embryo to the adult. Second, in the adult zebrafish pallium, miR-9 is exclusively expressed in qNSCs and maintains this cell state, which differs from the embryonic situation where miR-9 is expressed in proliferating NPCs and favors neurogenic activity ([@bib8], [@bib16], [@bib55]). Finally, this functional change is associated with a modification of miR-9 subcellular localization. Indeed, whereas miR-9 is detected cytoplasmically in embryonic and juvenile NPCs, we unexpectedly observed a concentration of miR-9 inside the nucleus of qNSCs, in tight correlation with the presence of the effector Ago proteins ([Figure 7](#fig7){ref-type="fig"}A). Juvenile NPCs already display quiescence characteristics ([@bib2], [@bib19]), thus, in addition to pinpointing an aged-dependent change in regulatory mechanisms of qNSCs, these data reinforce nuclear miR-9 expression as establishing a particular phase of the quiescence cycle, specific to mature NSCs. In the mouse DG, we observed an age-associated increase in the proportion of NSCs harboring miR-9 in their nucleus. However, at this point, because the temporal scales appear different, it remains an open question whether or not the same mechanisms are at play in the two species. Elucidating whether systemic factors are present that are capable of affecting miR-9 localization in an age-dependent fashion, or alternatively, if a NSC intrinsic clock could determine the switch of miR-9 preferential localization will shed more light on the mechanisms underlying the establishment and regulation of a mature NSC pool.

Although the canonical mechanism by which the Ago/RISC mediates gene expression is via mRNA silencing in the cytoplasm, several studies, largely performed in vitro, highlighted the presence of Ago complexes in the nucleus, although the precise mechanism of their shuttling is not fully understood ([@bib46], [@bib47], [@bib53], [@bib54], [@bib39]). Here, we provide evidence for the active nuclear/cytoplasmic shuttling of Agos in vivo in NSCs, and moreover, we show that this transport depends on the interaction of Agos with TNRC6 proteins. Additionally, we observed a surprising specificity of nuclear Agos to the population of qNSCs expressing nuclear miR-9 thus revealing their interdependency and overall indicating that Ago complexes that translocate to the nucleus must be loaded with miR-9. As nuclear localization of miR-9 and Ago is specific to qNSCs, and more precisely to a subset of qNSCs at any given time, it would be interesting to resolve how their nuclear/cytoplasmic shuttling is regulated in concert with the cell-cycle status of these cells and potentially in response to environmental cues from the neurogenic niche. Additionally, in-depth analysis of other NSC-expressed microRNAs and nuclear RISC components will be important to define this regulatory pathway.

Some classes of small non-coding RNAs such as PIWI-interacting RNAs (piRNAs) and small interfering RNAs (siRNAs) are recognized as regulating gene expression in both the cytoplasm and nucleus, however, a potential regulatory role for microRNAs outside of the canonical cytoplasmic pathway has just started to be explored ([@bib9], [@bib53]). Moreover, whether their presence in the nucleus is functional or rather just a mechanism for passive storage is still heavily debated ([@bib23], [@bib48]). In this study, we show that the dynamic transport of Ago and miR-9 functionally influences the activation status of the cell. Specifically, trapping Ago/miR-9 in the cytoplasm increases NSCs activation rate, mimicking miR-9 kd phenotype. Conversely, increasing miR-9 and Agos nuclear concentration using LMB significantly decreased NSC activation, a phenotype that is reversed by blocking miR-9. Altogether, this data supports an active role for nuclear Ago/miR-9 complexes in qNSCs ([Figure 7](#fig7){ref-type="fig"}B). Interestingly, and in line with our results, in vitro studies have demonstrated that nuclear Ago/microRNA complexes repress the transcription of cell-cycle activators thus leading to cell-cycle arrest ([@bib5]) opening to the intriguing possibility that an analogous nuclear Ago mechanism could be occurring in adult NSCs. Unravelling this mechanism and identifying miR-9/Ago targets in the nucleus will also shed light on the functional synergy between miR-9 and Notch signaling activity in the control of adult NSCs quiescence.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

Wild-type (AB) and *Tg(gfap:gfp)*^mi2001^ ([@bib6]) zebrafish were maintained using standard protocols and in accordance with Institute Guidelines for Animal Welfare. All experiments performed on zebrafish conformed to the official standards of the Department of Essonne (agreement \#A91-577). Three- to six-month-old adult fish were used for analysis unless otherwise stated. Mice were housed, bred, and treated according to the guidelines approved by the Home Office under the Animal (Scientific Procedures) Act 1986. All experimental procedures involving mice have been approved by the Animal Welfare and Ethical Review Panel of the National Institute for Medical Research.

BrdU Pulse-Chase and LY411575 Treatments {#sec4.2}
----------------------------------------

BrdU (1 mM, Sigma) was applied to the fish water at 28°C in the dark. Fish were subsequently transferred to a tank with fresh water during the chase period. LY411575 (10 μM, Stemgent) or DMSO carrier alone (0.4%--0.5%) was applied to the fish water for 48 hr at 28°C in the dark and refreshed once after 24 hr.

Ventricular Micro-injections and Electroporation {#sec4.3}
------------------------------------------------

Micro-injections into the adult pallial ventricle were performed on anaesthetized fish as described ([@bib51]). vivoMOs (Gene-tools) were injected at a concentration of 50 μM ([Table S1](#mmc1){ref-type="supplementary-material"}). Leptomycin B (Sigma) was resuspended in MeOH and fish were injected with either 2.0 nL of 100 nM LMB or MeOH (70%) and brains were analyzed 1 dpi. For electroporation, plasmid DNA was diluted to 2--4 μg/μL in TE pH8.0 and injected into the ventricle. Fish were then administered two electric pulses (70 V, 50 ms width, 1,000 ms space). For epistasis experiments, electroporation was carried out 2 hr prior to vivoMO injections.

In Situ Hybridization {#sec4.4}
---------------------

Adult zebrafish brains or embryos were fixed in 4% paraformaldehyde (PFA) overnight at 4°C. Mice were transcardially perfused with saline followed by 4% PFA and brains were dissected and postfixed with 4% PFA for 2 hr at 4°C. In situ hybridization (ISH) with DIG-labeled RNA probes were performed as described ([@bib2]). MicroRNA ISH using LNA probes (Exiqon) was performed according to [@bib33] on zebrafish embryos and on free-floating vibratome sections of the zebrafish adult telencephalon or mouse brain. MicroRNA ISH using the LNA 2′-O-Me modified probes (Ribotask) was performed on 50 μm free-floating vibratome sections following manufacturer instructions. miR-9 ISH on cultured mouse cells was performed as described ([@bib35]). All in situs were revealed using fast red (Sigma) or NBT/BCIP (Sigma). ISH probes are listed in [Table S2](#mmc1){ref-type="supplementary-material"}.

Immunohistochemistry {#sec4.5}
--------------------

Fluorescent immunohistochemistry on zebrafish brain sections was performed as described ([@bib11]). Perfused mouse adult brain tissue was sectioned coronally at 40 μm with a vibratome and subsequent immunohistochemistry was performed as described ([@bib3]). Immunohistochemistry on AH-NSCs was performed as described ([@bib37]). The primary antibodies used in this study are listed in [Table S3](#mmc1){ref-type="supplementary-material"}. For BrdU and PCNA staining, sections were incubated in either 2 N HCL for 30 min at 37°C or 1× HistoVT One (Nacalai Tesque) for 1 hr at 65°C. Goat or donkey secondary antibodies coupled to AlexaFluor dyes (Invitrogen) or Cy3/Cy5 dyes (Jackson Labs) were used (1:1,000) with DAPI (5 μg/μL) counterstain for nuclei.

qRT-PCR {#sec4.6}
-------

Total RNA enriched for small RNAs were extracted from adult telencephali (pool of 4), 1 month post-fertilization whole brains (pool of 5), and whole embryos (pool of 50--100) using the High Pure miRNA Isolation Kit (Roche). The following reagents were used for detection of the primiR-9 transcripts: Superscript II kit (Invitrogen) with Random Hexamer Primers (Thermo Scientific) for cDNA synthesis and LightCycler FastStart DNA Master SYBR Green I (Roche) for qRT-PCR. Primers used for qRT-PCR are listed in [Table S4](#mmc1){ref-type="supplementary-material"}. Efficiencies of each primer pair was evaluated by performing a dilution series experiment. The following reagents were used for detection of mature miRs: miRCURY LNA Universal cDNA Synthesis Kit (Exiqon) for cDNA synthesis and miRCURY LNA ExiLENT SYBR Green master mix (Exiqon) for qRT-PCR. For each transcript/miR, two biological and two technical replicates were performed using the LightCycler 2.0 Carousel-Based System (Roche). Crossing points were calculated using the LightCycler 4.0 software (Roche) (normalized to β-*actin* and *gapdh* for the primary transcripts and *U6* for the mature miRs) and all relative expression analysis was done using the REST ([@bib49]) software tool that determines significant differences between control and sample groups-based crossing points using a randomization algorithm.

AH-NS Cell Culture {#sec4.7}
------------------

AH-NSCs were isolated from 6-week-old C57Bl6 mice using the neural tissue dissociation kit (Miltenyi Biotec) and cultured as described previously ([@bib37]). Briefly, cells were plated at a density of 30,000 cells/cm^2^ onto laminin coated coverslips (2 μg/mL) in normal NSC proliferation medium (EGF and FGF at 20 ng/mL; Peprotech). To induce quiescence, fresh NSC medium without EGF and with 20 ng/mL BMP4 (R&D Systems) was added. BMP4 containing media was changed daily. Cells were fixed in 4% PFA for 10 min.

Imaging, Cell Counting, and Statistics {#sec4.8}
--------------------------------------

Images were taken using a Zeiss LSM700 (Zeiss) confocal microscope using 20×, 40× (oil), or 63× (oil) objectives. Images were processed using the ZEN (Zeiss) and Fiji software. Cell counts on zebrafish brains were carried out manually on 50 μm z stacks from three serial sections from telencephali with n = 3 telencephali per condition unless otherwise stated. Imaris (Bitplane-Oxford Instruments) was used for all mouse DG cell counts. Briefly, spots were added automatically in the Sox2 channel to identify all Sox2^+^ cells. To determine nuclear miR-9, a filter was added to the spots identifying Sox^+^ cells based on the center intensity of the miR-9 channel. A center intensity of \>55 was determined to be nuclear miR-9 expression. Analysis of Ago2 and miR-9 expression in AH-NSCs was carried out using the Fiji/ImageJ software. The subcellular distribution of Ago2 and miR-9 was analyzed using the Intensity Ration Nuclei Cytoplasm Tool plugin. For all analyses, n = 3 independent wells per sample with five confocal fields analyzed per well. For all quantitative experiments, statistical analysis was carried out using Excel and InVivoStat ([@bib14]). Experimental data are expressed as means ± 95% confidence interval. Associations were determined using χ^2^ tests for association. Comparisons between groups were made using one-way ANOVAs followed by Bonferroni post hoc correction.
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![Dynamic Expression of miR-9 in qNSCs\
(A) qRT-PCR analysis of the seven miR-9 transcripts in 48 hr post-fertilization (hpf) embryos, 1 month post-fertilization (mpf) juvenile brains, and 3 mpf adult brains with the expression of each transcript over the sum expression of all transcripts.\
(B) ISH against pri-miR-9-6 on a cross-section of the telencephalon illustrating its expression restricted to the ventricular region (blue). Scale bar, 100 μm.\
(C) Sections through the medial region of the dorsal telencephalon showing ISH with a mature miR-9 LNA probe (magenta) and double fluorescent immunostaining for *gfap*:GFP (green) and MCM5 (light blue). miR-9 expression is restricted to qNSCs (*gfap*^+^, MCM5^−^; red arrows) and never observed in aNSCs (*gfap*^+^, MCM5^+^; white asterisk). Some qNSCs are devoid of miR-9 signal (yellow arrows). Scale bar, 10 μm.\
(D) Proportion of qNSCs (*gfap*^+^, MCM5^−^; dark gray) and aNSCs (*gfap*^+^, MCM5^−^; light gray) in the total, miR-9^+^ or miR-9^−^ NSC population demonstrating that miR-9 expression is associated with quiescence.\
(E) Percentage of qNSCs that are miR-9^+^ or miR-9^−^.\
(F) Experimental design to assess miR-9 expression dynamics across the NSCs activation/quiescence cycle.\
(G) Representative image of BrdU^+^ (light blue), miR-9^+^ (pink), and GS^+^ (green) NSC 10 days after BrdU pulse. Scale bar, 5 μm.\
(H) Percentage of miR-9^+^ cells among BrdU^+^ NSCs after different chase period. ^∗^p \< 0.05; one-way ANOVA with Bonferroni post hoc correction. Data are represented as mean ± 95% confidence interval (CI); n = 3 brains per condition.](gr1){#fig1}

![miR-9 Maintains NSC Quiescence\
(A) Percentage of NSCs expressing miR-9 at 1, 2, 3, and 5 days post injection (dpi) of the control vivoMO (light gray bars) or miR-9 vivoMO (dark gray bars).\
(B) Percentage of aNSCs (MCM5^+^, *gfap*) over the total NSCs population (*gfap*^+^) 1, 2, 3, and 5 dpi of the control vivoMO (light gray bars) or miR-9 vivoMO (dark gray bars).\
(C) Double immunostaining for *gfap*:GFP (green) and MCM5 (light blue) in control (top) and miR-9 (bottom) vivoMO-injected brains. Scale bar, 20 μm.\
(D) Average raw number of *gfap*^+^ NSCs per section in control (light gray bar) and miR-9 (dark gray bar) vivoMO-treated brains at 5 dpi.\
(E and F) Analysis of the fate of activated cells upon miR-9 kd. Fish were administered BrdU for 48 hr following injection of vivoMOs and analyzed after 30 days of chase. (E) Mean number of BrdU^+^ per brain section in control (light gray bar) and miR-9 (dark gray bar) vivoMO-treated brains. (F) Percentage of BrdU^+^ cells that remain NSCs (*gfap*^+^), or acquired a neuronal fate (HuC/D^+^) or other fate in control (light gray bar) and miR-9 (dark gray bar) vivoMO and brains after a 30 day chase. ^∗^p \< 0.05, ^∗∗^p \< 0.01; one-way ANOVA with Bonferroni post hoc correction. Data are represented as mean ± 95% CI; n = 3 brains per condition.](gr2){#fig2}

![miR-9 Potentiates Notch Activity to Maintain Quiescence\
(A and B) Boxplots of qRT-PCR analysis showing the relative change in expression of the miR-9 transcripts and the Notch target *her4* (A) and of the mature miR-9-5p/3p compared to a U6 small nucleolar RNA (snoRNA) control (B) after a 48 hr treatment with LY411575 or DMSO (control). The top and the bottom of each box indicate the 75^th^ and 25^th^ percentiles, respectively, and the dotted line indicates the median.\
(C) Expression of miR-9 (magenta) in a GS^+^ (green)/PCNA^+^ (light blue) aNSC (yellow arrow) after a 48 hr LY treatment. Scale bar, 5 μm.\
(D) Proportion of qNSCs (*gfap*^+^, MCM5^−^; dark gray) and aNSCs (*gfap*^+^, MCM5^+^; white) in the miR-9^+^ or miR-9^−^ NSC population after a 48 hr treatment with LY or DMSO.\
(E) ISH for *her4* 2 dpi with the control (top) or miR-9 (bottom) vivoMO. Right panels are close-ups of the region within the red box. Scale bars, 100 μm (left); 50 μm (right).\
(F) Epistasis experiment combining miR-9 kd with overexpression of Notch intracellular domain (NICD). The graph shows the percentage of qNSCs (dark gray) and aNSCs (white) in brains injected with the control or miR-9 vivoMO and in cells overexpressing NICD (NICD^+^) or not (NICD^−^). ^∗^p \< 0.05, ^∗∗^p \< 0.01; one-way ANOVA with Bonferroni post hoc correction. Data are represented as mean ± 95% CI; n = 3 brains per condition.](gr3){#fig3}

![miR-9 Is Nuclear in Mature qNSCs and Is Significantly Associated with the Nuclear Localization of the RISC Effector Ago\
(A) Representative image of ISH for miR-9 (magenta) and double immunostaining for PCNA (light blue) and GS (green) with nuclear DAPI counterstaining (dark blue) highlighting the presence of miR-9 in the nucleus of qNSCs (yellow arrow) and not in the nucleus of aNSCs (red arrow). Scale bar, 10 μm.\
(B) Sections through the medial region of the dorsal telencephalic ventricle of a 48 hpf embryo, a 1 mpf juvenile, and a 3 mpf adult zebrafish illustrating an ISH of miR-9 (magenta) alone (top) and together with DAPI counterstaining in gray (bottom). Scale bar, 5 μm.\
(C) Proportion of cells showing strong nuclear localization of Ago (blue) or mostly cytoplasmic localization of Ago (light gray) in miR-9^+^ versus miR-9^−^ NSCs populations, illustrating the association between nuclear Ago localization and miR-9 expression.\
(D) ISH of miR-9 (magenta) and double fluorescent immunostaining for *gfap*:GFP (green) and Ago (ab57113, light blue) with nuclear DAPI counterstaining (dark blue). Strong nuclear Ago localization is observed in miR-9^+^ NSCs (yellow arrows) in contrast to cytoplasmic Ago localization in miR-9^−^ NSCs (white asterisk and gray arrow). Scale bar, 20 μm.\
(E) Double fluorescent immunostaining for *gfap*:GFP (green) and Ago (light blue) with nuclear DAPI counterstaining (dark blue) in conditions of miR-9 kd (bottom) when compared to controls (top). NSCs with strong nuclear Ago staining (yellow arrowheads) are lost in miR-9 MO-treated brains, while the nuclear signal for Ago in neuronal cells is not affected by miR-9 kd (white asterisks). Scale bar, 10 μm.\
(F) Quantification of the percentage of NSCs displaying a strong nuclear Ago signal 2 dpi of the control or miR-9 vivoMO. ^∗∗^p \< 0.01; one-way ANOVA with Bonferroni post hoc correction. Data are represented as mean ± 95% CI; n = 3 brains per condition.](gr4){#fig4}

![Active Nucleo-Cytoplasmic Shuttling of Ago and miR-9 Impacts the Quiescent State of NSCs\
(A) Scheme of the zebrafish TNRC6 protein with the cloned GW-rich Ago binding domain highlighted in purple.\
(B) Triple immunofluorescence of GFP (green), Ago (magenta), and PCNA (light blue) with nuclear DAPI counterstaining (dark blue) on a representative cell electroporated with a control construct (*her4:gfp*, top, yellow arrow) or the dominant-negative TNRC6 (DN-TNRC6) construct (*her4:dn-tnrc6a-gfp*, bottom, white arrow). Scale bar, 5 μm.\
(C) Quantification of the data from (B), showing the percentage of electroporated cells with mostly nuclear (blue) or cytoplasmic (gray) Ago signal; n = 10 brains per condition.\
(D) Percentage of cells electroporated with the *her4:gfp* (top) or *her4:dn-tnrc6-gfp construct* (bottom) in which miR-9 is detected in the nucleus (dark blue), cytoplasm (gray) or absent (light blue); n = 10 brains per condition.\
(E) Triple fluorescent immunostaining of *gfap*:GFP (green), Ago (magenta), and PCNA (light blue) with nuclear DAPI counterstaining (dark blue) after ventricular injection of LMB (bottom) or a MeOH control (top). Yellow arrowheads highlight NSCs with a strong nuclear Ago signal. Scale bar, 20 μm.\
(F and G) Quantification of data from (E) 24 hpi with LMB or MeOH as a control; n = 5 brains per condition. (F) Percentage of NSCs (*gfap*^+^) with strong nuclear Ago signal. (G) Percentage of aNSCs (PCNA^+^, *gfap*^+^) among NSCs (*gfap*^+^).\
(H) Percentage of aNSCs (PCNA^+^, *gfap*^+^) among NSCs (*gfap*^+^) upon combination of LMB or MeOH injections with vivoMO injections. n = 4 brains per condition.\
(I) Quantification of the data from (B) of the percentage of GFP^+^ aNSCs out of total GFP^+^ NSCs; n = 10 brains per condition.\
(J) Percentage of aNSCs (MCM2^+^, GFP^+^) out of total NSCs (GFP^+^) after electroporation with the control *her4:gfp* or *her4:dn-tnrc6-gfp* construct and subsequent MO injections. n = 7 brains per condition. ^∗^p \< 0.05, ^∗∗^p \< 0.01; one-way ANOVA with Bonferroni post hoc correction. Data are represented as mean ± 95% CI.](gr5){#fig5}

![Nuclear Localization of miR-9 and Ago2 Also Correlates with Quiescence in Adult Mouse NSCs\
(A and B) Representative high-magnification two-dimensional images of the 10-month DG (A) and SEZ (B) on the XY (top) and YZ (bottom) axes (yellow line = position of the YZ image) with Sox2 (light blue) and GFAP (green) immunofluorescence, miR-9 ISH (magenta), and a nuclear DAPI counterstain (gray). Scale bars, 10 μm.\
(C) Percentage of NSCs (Sox2^+^, GFAP^+^) with nuclear miR-9 in the DG of 2- and 10-month mouse brains; n = 2 brains per age. ^∗^p \< 0.05; one-way ANOVA with Bonferroni post hoc correction. Data are represented as mean ± 95% CI.\
(D) Immunofluorescence for Ago2 (magenta) (left) and ISH for miR-9 (light blue) (right) and a nuclear DAPI counterstain (gray) on proliferating (top) and quiescent (bottom) adult hippocampal neural stem cells (AH-NSCs). Scale bars, 10 μm.\
(E and F) Percentage of NSCs with high nuclear concentration of Ago2 (E) or miR-9 (F) in proliferation-promoting or quiescence-promoting conditions.\
(G) Relative distribution of Ago2 (left) and miR-9 (right) signal intensities in the cytoplasm (dark gray) and nucleus (blue) in proliferating or quiescent NSCs; n = 15 confocal fields taken from 3 independent coverslips (5 fields/coverslip) in each condition; total proliferating NSCs = 2,411, total quiescent NSCs = 860.](gr6){#fig6}

![Model for Ago/miR-9 Complexes in Regulating NSCs Quiescence\
(A) miR-9 is concentrated in the cytoplasm of all juvenile NSCs (qNSCs and aNSCs). In the adult, miR-9 is concentrated in the nucleus of ∼50% of the qNSCs. Adult qNSCs cycle between miR-9^+^ and miR-9^−^ states.\
(B) In adult qNSCs (left), Ago (light purple)/miR-9 (magenta) complexes are actively shuttled into the nucleus by TNRC6 proteins (dark green). Enhanced transport of Ago/miR-9 complexes into the nucleus anchors the NSCs in quiescence via directly or indirectly activating *her4* expression in concert with Notch3 and through other unknown mechanisms, perhaps by influencing chromatin state. Upon transport of Ago/miR-9 complexes into the cytoplasm, the NSC is activated (right) and miR-9 is no longer detectable, demonstrating that TNRC6-mediated shuttling of Ago/miR-9 is necessary for balancing the quiescent versus activated NSC state.](gr7){#fig7}
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